Michael Andreeff Selected Research

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

11/2022	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
4/2022	Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
4/2022	Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
1/2022	Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
1/2022	Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
1/2022	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
1/2022	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
1/2022	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
1/2022	Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
1/2022	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Andreeff Research Topics

Disease

160	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 01/2002
120	Neoplasms (Cancer) 02/2022 - 01/2002
103	Leukemia 01/2022 - 02/2002
18	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 06/2002
17	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2002
17	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2019 - 06/2002
16	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2002
16	Hematologic Neoplasms (Hematological Malignancy) 03/2021 - 01/2002
16	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020 - 04/2002
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 06/2002
13	Hypoxia (Hypoxemia) 01/2020 - 08/2009
11	Acute Promyelocytic Leukemia 01/2022 - 03/2004
10	Carcinogenesis 01/2022 - 09/2003
10	Lymphoma (Lymphomas) 01/2015 - 10/2004
8	Philadelphia Chromosome 10/2011 - 04/2002
6	Blast Crisis (Blast Phase) 10/2015 - 02/2006
5	Inflammation (Inflammations) 10/2019 - 03/2006
5	Myeloid Leukemia (Leukemia, Myelocytic) 01/2017 - 01/2002
5	Glioma (Gliomas) 04/2013 - 04/2005
5	Mitochondrial Diseases (Mitochondrial Disease) 05/2008 - 12/2005
4	Disease Progression 01/2022 - 06/2008
4	AIDS-Related Complex (ARC) 01/2019 - 01/2011
4	Residual Neoplasm 01/2018 - 01/2017
4	Pancreatic Neoplasms (Pancreatic Cancer) 09/2010 - 10/2002
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 10/2018
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 03/2003
3	Exanthema (Rash) 01/2021 - 04/2014
3	Fatigue 01/2021 - 09/2006

Drug/Important Bio-Agent (IBA)

66	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2002
27	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2022 - 04/2002
22	venetoclaxIBA 11/2022 - 03/2014
20	TriterpenesIBA 11/2014 - 01/2002
15	bardoxoloneIBA 04/2012 - 01/2002
14	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 02/2008
14	Pharmaceutical PreparationsIBA 12/2017 - 09/2003
12	LigandsIBA 11/2021 - 07/2002
12	Phosphotransferases (Kinase)IBA 01/2021 - 06/2003
12	bardoxolone methylIBA 11/2014 - 01/2002
11	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 07/2002
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2018 - 05/2002
10	CaspasesIBA 11/2014 - 12/2002
10	SurvivinIBA 08/2013 - 09/2003
10	AcidsIBA 11/2007 - 09/2003
9	Tyrosine Kinase InhibitorsIBA 04/2022 - 06/2003
9	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 06/2013
9	Biological ProductsIBA 01/2022 - 07/2002
9	Oxygen (Dioxygen)IBA 10/2021 - 07/2008
9	ABT-737IBA 09/2021 - 11/2006
9	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 06/2006
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2002
8	CytokinesIBA 01/2020 - 09/2002
8	fms-Like Tyrosine Kinase 3IBA 12/2017 - 04/2006
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 03/2009
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 04/2005
7	bcr-abl Fusion ProteinsIBA 01/2016 - 07/2002
7	fludarabineIBA 07/2015 - 04/2002
6	EnzymesIBA 01/2022 - 01/2009
6	Decitabine FDA Link 01/2022 - 08/2003
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 03/2006
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 02/2006
6	MicroRNAs (MicroRNA)IBA 01/2018 - 03/2008
6	Messenger RNA (mRNA)IBA 01/2018 - 06/2002
6	nutlin 3IBA 01/2017 - 08/2006
5	NF-kappa B (NF-kB)IBA 01/2022 - 01/2002
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 06/2009
5	selinexorIBA 11/2020 - 01/2015
5	Adenosine Triphosphate (ATP)IBA 01/2013 - 12/2002
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2012 - 08/2005
5	EstersIBA 12/2010 - 01/2002
5	PPAR gammaIBA 06/2010 - 07/2002
4	MethyltransferasesIBA 01/2021 - 06/2009
4	Galectin 3 (LGALS3)IBA 06/2019 - 04/2016
4	Rituximab (Mabthera)FDA Link 01/2019 - 05/2003
4	CateninsIBA 01/2019 - 04/2014
4	ChemokinesIBA 04/2016 - 12/2006
4	ProdrugsIBA 04/2016 - 01/2011
4	Bortezomib (Velcade)FDA Link 02/2016 - 10/2003
4	Cyclin D1IBA 01/2015 - 09/2003
4	Monoclonal AntibodiesIBA 03/2014 - 06/2005
4	Caspase 8 (Caspase-8)IBA 02/2014 - 05/2005
4	Antisense OligonucleotidesIBA 08/2013 - 02/2009
4	Chemokine CXCL12IBA 01/2013 - 04/2005
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2012 - 04/2002
4	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2010 - 04/2005
4	Mitogen-Activated Protein KinasesIBA 03/2010 - 05/2002
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2008 - 09/2002
4	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 12/2007 - 03/2004
3	Radioisotopes (Radionuclides)IBA 02/2022 - 01/2018
3	GD2 gangliosideIBA 01/2022 - 06/2012
3	VaccinesIBA 01/2022 - 04/2003
3	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 12/2011
3	NucleophosminIBA 01/2021 - 12/2013
3	Drug CombinationsIBA 01/2021 - 05/2014

Therapy/Procedure

88	Therapeutics 05/2022 - 04/2002
42	Drug Therapy (Chemotherapy) 01/2022 - 03/2003
5	Induction Chemotherapy 01/2022 - 03/2003
4	Transplantation 01/2022 - 01/2012
4	Radiotherapy 01/2021 - 08/2004
4	Stem Cell Transplantation 01/2018 - 12/2011
3	Immunotherapy 01/2022 - 04/2003